The approval of the first oncolytic viral therapy, Imlygic, in the United States and EU5 in 2015 and 2016, respectively, marks a significant milestone for cancer vaccines and viral therapies, making these therapies exciting to watch. Cancer Vaccines and Viral Therapies provides comprehensive multi-indication coverage of currently available cancer vaccines (Provenge in the United States and Imlygic in the United States and EU5) and analysis of their ongoing clinical development across the oncology indications. In addition, analysis of late-phase emerging therapies and their future positioning in oncology is provided based on insights from interviewed thought leaders and analysis of secondary market research sources. This analysis uniquely enables a comparison of the potential of the therapies in this drug class across a breath of indications in addition to determining their total peak-year sales across oncology indications.

Table of contents

  • Therapeutic Vaccines And Viral Therapy - Landscape & Forecast - Special Topic Report

Author(s): Karen Pomeranz, PhD

Karen Pomeranz is a senior business insights analyst analyst in the oncology team at Decision Resources Group. She has worked on a breadth of indications including glioma, hepatocellular carcinoma, gastrointestinal stromal tumor, malignant melanoma, renal cell carcinoma, breast cancer, and colorectal cancer. She has worked on several products lines as well as with the Decision Resources Group consulting team on many projects.

Her previous work experience includes conducting scientific research at Imperial College, London and Tel-Aviv University. Dr. Pomeranz holds an M.Sc. from Tel-Aviv University and a Ph.D. from Imperial College, London.